热门资讯> 正文
X4 Pharmaceuticals将裁员50%
2025-09-17 19:33
- X4 Pharmaceuticals (NASDAQ:XFOR) has announced a restructuring program to align resources with its long-term strategy to complete the Phase 3 4WARD trial for chronic neutropenia.
- The plan includes cutting 50% of its workforce, expected to save about $13M annually. As part of the workforce reduction, chief legal & compliance officer Natasha Thoren; chief operating officer Mary DiBiase; and chief commercial officer Mark Baldry will be exiting the firm. John Volpone has been appointed chief operating officer, in addition to his current role as president.
- Chief medical officer Christophe Arbet‑Engels is resigning for personal reasons and will remain available to support transition activities. Adam Craig, executive chairman, will oversee clinical development.
- XFOR +2.49% premarket to $3.29
- Source: Press Release
More on X4 Pharmaceuticals
- Seeking Alpha’s Quant Rating on X4 Pharmaceuticals
- Historical earnings data for X4 Pharmaceuticals
- Financial information for X4 Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
